Link Technologies Ltd to Exhibit at the Sixth Cambridge Symposium on Nucleic Acids Chemistry and Biology

Published: Aug 17, 2011

BELLSHILL, SCOTLAND, 17 August 2011: Link Technologies Ltd, an ISO 9001:2008 certified specialist oligonucleotide reagent manufacturer, has today announced that it will be heavily involved in this year’s Cambridge Symposium on Nucleic Acids Chemistry and Biology, Cambridge, UK (4-7 September 2011). As well as exhibiting and presenting a poster at the event, the company is also sponsoring a student bursary award worth £500. Several Link Technologies specialists will be available to answer questions and discuss requirements, including Dr Catherine McKeen (Product Manager), Dr Michaela Downie (Key Account Executive) and Sheena Aitken (Applications Scientist). Of particular interest to attendees will be the scientific poster presented by the team entitled ‘Tocopherol (Vitamin E) Modified Oligonucleotides’, which discusses the benefits of using tocopherol to facilitate the delivery of oligonucleotides into cells. To learn more about the DNA, RNA, PNA & UNA synthesis and modification solutions offered by Link Technologies, and how they can help you achieve your diagnostic or research goals, please visit their stand at the event.

You can find out more about Link Technologies at You can also follow us on twitter @linktechdna and keep track of the latest news and offers by visiting our blog.

About Link Technologies Ltd

Link Technologies Ltd is a leading kilo-scale supplier of speciality reagents for oligonucleotide synthesis and modification, all to the ISO 9001:2008 quality certification. The company’s main markets are university and commercial research departments, plus, increasingly, larger Contract Manufacturing Organisations (CMOs) in the biotech sector. Link has also forged successful links to academia working closely with many UK universities. In tandem with internal research and development, the Company has an excellent record in bringing in-licence products to market with various worldwide commercial partners.

For further information see:

Back to news